Being at the intersection of health care and patents, two subjects that concern myself personally, I found this story interesting. Basically, Humira is being priced into the stratosphere in the U.S. because of a combination of patent leveraging and the inability of Medicare to negotiate pricing, resulting in sob stories of people who need the drug and not being able to afford it.
I had two takes on it, the patent take and the health care take, posted at two different places. I’ve made it easy for you by putting both here together.
One Article About Big Pharma, Two Hot Takes